SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pasithea Therapeutics Corp. (KTTAW) has a negative trailing P/E of 0.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -387,383.17%.
Criteria proven by this page:
- VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E 0.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -387,383.17%).
- Trailing Earnings Yield -387,383.17% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 37/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KTTAW
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA2,741.0
Per Share Data
EPS (TTM)$-2,905.37
Book Value / Share$7,853.68
Revenue / Share$0.00
FCF / Share$-219.26
Yields & Fair Value
Earnings Yield-387,383.17%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-797.9 |
0.00 |
203.23 |
0.00 |
- |
| 2021 |
-18.7 |
-0.01 |
0.79 |
2,703.81 |
- |
| 2022 |
-1.2 |
0.00 |
0.38 |
0.00 |
- |
| 2023 |
-0.6 |
-0.03 |
0.40 |
0.00 |
- |
| 2024 |
-0.2 |
-0.79 |
0.23 |
0.00 |
- |
| 2025 |
0.0 |
0.00 |
0.00 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-0.06 |
$0.00 |
$-40.98K |
- |
| 2021 |
$-1.89 |
$15.06K |
$-2.17M |
-14433.9% |
| 2022 |
$-10.34 |
$486.56K |
$-13.06M |
-2683.4% |
| 2023 |
$-13.01 |
$0.00 |
$-15.96M |
- |
| 2024 |
$-12.69 |
$0.00 |
$-13.9M |
- |
| 2025 |
$-2.91 |
$0.00 |
$-20.43B |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.82 |
$-0.82 – $-0.82 |
$0.00 |
$0.00 – $0.00 |
1 |
| 2027 |
$-0.87 |
$-0.87 – $-0.87 |
$0.00 |
$0.00 – $0.00 |
1 |
| 2028 |
$-2.30 |
$-2.30 – $-2.30 |
$0.00 |
$0.00 – $0.00 |
1 |
